M&A in the CMC Services Industry: Implications and Outlook

In the three-year period 2014-2016 there were 101 acquisitions of CMC services companies, including dose and API manufacturing, packaging, logistics, formulation and analytical services. Learn how M&A in the bio/pharma contract services industry is likely to play out over the next two years.

How can small/mid-size pharma companies get attention of top CMOs?

A lot depends on who is getting the approvals and the nature of… Jim Miller weighs in

How big is the market for…?

We often are asked the size of the market for various segments of the bio/pharma contract services industry. In response, we’ve developed a resource page that addresses… Learn more.

Follow the Money to Pharmaceutical Opportunities

Spotlight on BioCryst Pharmaceuticals, Inc.

BioCryst plans to raise $45 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds for future clinical development of BCX7353, for continued development of its second-generation compounds for HAE and… read on.

CMOs and CROs Have Different Trajectories

A growing number of observers, including the Wall Street analysts that follow the publicly-traded CROs and CMOs, have made statements recently suggesting that the CMO industry is following the trajectory that… See Jim Miller’s Outsourcing Outlook Archive.

Testimonial

“We are nearly fully booked for the next 18+ months, with full credit going to the PharmSource Lead Sheet.”
Read more from other satisfied clients.

Not So NICE:

European Drug Pricing to Impact CMO Profitability and Performance. Learn more about how European drug-rationing policies could affect pharmaceutical manufacturing profitability – and future operations – in the EU, US and elsewhere.

Dose CMOs by the Numbers

The contract dose manufacturing universe includes 280 companies headquartered primarily in North America, Europe, Japan and India. Nearly 61% of those companies pursue contract manufacturing as their primary business, while the others contract manufacture in facilities where they produce their own products. Learn more about the implications for the dose CMO industry.

ADC Therapeutics

ADC Therapeutics reports positive interim results from a Phase I study with ADCT-301 for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphoma. Become a subscriber and have leads like this one delivered weekly.